Could This Biosimilar Drug Be Novartis' Next Blockbuster?

[cafead]

via

• Novartis’ biosimilar candidate to Eylea has proven just as safe and effective.
• The medicine could generate $500 million in annual sales for the Swiss drugmaker.
• Income investors may find Novartis’ stock intriguing for this and other reasons.

article source